186 related articles for article (PubMed ID: 9435812)
1. [Progestational agents and bone metastasis in breast cancer].
Leriche N; Bonneterre J
Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
[TBL] [Abstract][Full Text] [Related]
2. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
3. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Noguchi S; Yamamoto H; Inaii H; Koyama H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
5. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
6. The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.
Pritchard KI
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4356s-4359s; discussion 4411s-4412s. PubMed ID: 11916225
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
[TBL] [Abstract][Full Text] [Related]
8. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
9. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
[TBL] [Abstract][Full Text] [Related]
10. [A case of breast cancer with metastasis of multiple organs showing marked efficacy of medroxyprogesterone acetate (MPA)].
Shimada K; Karaki Y; Ansai Y; Hino K; Yamashita Y; Fujimaki M
Gan To Kagaku Ryoho; 1996 Apr; 23(5):623-6. PubMed ID: 8678522
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds.
Ouatas T; Halverson D; Steeg PS
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3763-72. PubMed ID: 14506169
[TBL] [Abstract][Full Text] [Related]
12. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
13. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
14. [Hormonal control of disseminated breast cancer].
Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
Sov Med; 1990; (6):94-7. PubMed ID: 2144368
[No Abstract] [Full Text] [Related]
15. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
16. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC
Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
[TBL] [Abstract][Full Text] [Related]
17. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
[TBL] [Abstract][Full Text] [Related]
19. [Current status of hormonotherapy of metastatic cancer of the breast].
Namer M
Bull Cancer; 1989; 76(1):65-73. PubMed ID: 2713517
[TBL] [Abstract][Full Text] [Related]
20. [A case of breast cancer with multiple metastases successfully treated by medroxyprogesterone acetate with intermittent intra-arterial infusion low-dose chemotherapy to hepatic metastasis].
Kusama M; Kaise H; Nakayama S; Oota D; Shimizu H; Aoki T; Koyanagi Y
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2243-7. PubMed ID: 11142170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]